Targeting of Wnt–β-Catenin Pathway in Recurrent Ameloblastoma

Samuel J. Klempner

Mass General Brigham Cancer Institute, Boston

Moh’d Khushman

Washington University in St. Louis, St. Louis

Kyriakos P. Papadopoulos

South Texas Accelerated Research Therapeutics, San Antonio

Meredith P. Pelster

Sarah Cannon Research Institute, Nashville

Jordi A. Rodon

University of Texas M.D. Anderson Cancer Center, Houston

Rona Yaeger

Shivaani Kummar

Sunil Sharma

David Bajor

University Hospitals Seidman Cancer Center, Cleveland

Dennis Hsu

University of Pittsburgh Medical Center, Pittsburgh

Ranjodh S. Dhami

Massachusetts General Hospital, Boston

Bayan Alzumaili

Massachusetts General Hospital, Boston

Jeremy D. Kratz

Carbone Cancer Center, University of Wisconsin, Madison

Varun Monga

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

Alexander Philipovskiy

Florida Cancer Specialists, Lake Mary

Jorge Ramos

Parabilis Medicines, Cambridge, MA

Amber Wells

Parabilis Medicines, Cambridge, MA

Marie H. Nguyen

Parabilis Medicines, Cambridge, MA

Jonathan B. Hurov

Parabilis Medicines, Cambridge, MA

Michael Cecchini

Yale University School of Medicine, New Haven, CT